Orencia (abatacept) — J0129

Orencia and related infused biologics

Orencia (abatacept) bills under J0129, 10 mg per billing unit, from Bristol Myers Squibb. It is a selective T-cell costimulation modulator, one of several IV biologics used for rheumatoid arthritis and psoriatic arthritis alongside Remicade, Actemra IV and Simponi Aria; no abatacept biosimilar has been approved.

A payer’s step-therapy rule decides which agent a patient starts on, not a clinical preference: 28 of 29 payers in the Clearance corpus require methotrexate or another conventional DMARD first, and some also require a documented trial of a preferred biologic. CareFirst requires “documented inadequate response or intolerable adverse event with Entyvio, Ilumya, Remicade, and Simponi Aria where the product's indications overlap,” and Independence requires documented failure, contraindication or intolerance to infliximab (Remicade) or golimumab (Simponi Aria) for a biologic-naive rheumatoid arthritis patient (see Coverage & access).

Vials and NDCs

One vial size covers every band. The 500, 750 and 1,000 mg doses draw 2, 3 and 4 vials with nothing discarded, and the billing-units calculator returns the same whole-vial count for any weight.

This reference does not recommend one biologic over another. The payer's own step-therapy rule decides which agent a given patient can start on, and it can require methotrexate, a preferred biologic, or both before abatacept is authorized.

Orencia dosing

Adult rheumatoid arthritis and psoriatic arthritis follow a body-weight band, not a titration: 500 mg under 60 kg, 750 mg from 60 to 100 kg, 1,000 mg over 100 kg, each at weeks 0, 2 and 4 then every 4 weeks. Every band draws a whole number of 250 mg vials, so JZ applies at every infusion.

Weight-based dosing for pJIA and GvHD prophylaxis

Two indications are dosed per kilogram instead of by adult band. Polyarticular JIA at 6 years and older is 10 mg/kg for a patient under 75 kg, switching to the adult bands at 75 kg and up (maximum 1,000 mg). Acute GvHD prophylaxis is 10 mg/kg (maximum 1,000 mg) at 6 years and older, or 15 mg/kg on day -1 then 12 mg/kg on days 5, 14 and 28 for a patient 2 to under 6 years, each infusion given over 60 minutes and still billed 96365 alone.

A per-kilogram dose rarely lands on a whole vial. A 30 kg pJIA patient draws 300 mg from two 250 mg vials, using 30 units and discarding 200 mg (20 units) on a JW line, the only place JW applies on this page (see the billing-units calculator).

Pre-treatment and concomitant therapy

• Screen for latent tuberculosis before starting; treat a positive result before the first dose.
• Screen for viral hepatitis before starting.
• Update vaccinations before starting; live vaccines are not given during treatment or within 3 months after stopping.
• Rheumatology use: monotherapy or with a conventional DMARD such as methotrexate, never with a JAK inhibitor, TNF antagonist or other biologic DMARD. GvHD prophylaxis: given with a calcineurin inhibitor and methotrexate, plus EBV antiviral prophylaxis starting before the first dose and continuing six months after transplant.

Need the units for a patient's dose? Convert dose to J0129 billing units →

Orencia billing reference

HCPCS

J0129 bills 10 mg per unit. The three adult bands are 500 mg (50 units), 750 mg (75 units) and 1,000 mg (100 units); a per-kilogram pJIA or GvHD dose is rounded to the nearest whole unit.

NDC

One vial size, one NDC. See the vial table in Drug & products above. The 11-digit claim-form NDC is 0003-2187-10, and it stays the same across every weight band, since each band is a different vial count of the same 250 mg vial.

Administration

Administration is a single code, not a choice: every Orencia infusion, the 30-minute rheumatology infusion and the 60-minute GvHD prophylaxis infusion alike, bills 96365 alone. CPT 96365–96366 carries the complete code definitions.

Modifiers

JZ: required when no drug is discarded. JW: required for documented waste.

The three adult bands draw a whole number of 250 mg vials (2, 3 or 4) with nothing left over, so JZ applies on every adult infusion. A per-kilogram pJIA or GvHD dose can land between vials; the 30 kg pJIA example above discards 200 mg (20 units) on a JW line. The J0129 MUE is 100 units (1,000 mg) a day, the labeled maximum.

Full unit, vial and modifier math for any dose: calculate Orencia billing units →

Claim form

CMS-1500 / 837P field map for a separately payable J0129 claim.

Orencia coverage

The Clearance corpus carries 29 payers and 535 rules for abatacept, the deepest step-therapy corpus in this reference after infliximab. 26 of the 29 require prior authorization, and 28 require methotrexate or another conventional DMARD before abatacept.

• 26 of 29 commercial payer policy sets require prior authorization; 3 do not say clearly, so confirm those on the call
• 28 of 29 payers require methotrexate or another conventional DMARD before abatacept, and several then require a trial of one or two preferred biologics.
• 15 rules set a quantity limit, most writing the vial or unit ceiling for each weight band, and 3 require reauthorization on documented response.
• 15 rules address site of care, framed as whether the patient can self-administer the subcutaneous syringe instead of the IV infusion.

Prior authorization, step therapy and reauthorization

Methotrexate or a conventional synthetic DMARD comes first at 28 of 29 payers. Anthem requires “inadequate response to methotrexate titrated to maximally tolerated dose,” BCBS Florida and BCBS HCSC both require “maximally tolerated methotrexate (e.g., titrated to 25 mg weekly),” and BCBS Arkansas requires an inadequate response “(trial of greater than or equal to 3 months) to at least one conventional synthetic DMARDs.”

Several payers then require a preferred agent on top of methotrexate: Anthem requires “trial and inadequate response or intolerance to two (2) preferred agents,” and Aetna requires failure, intolerance or a contraindication to “all of the following available equivalent alternative targeted immune modulators (one-month trial each): Avtozma, Simponi Aria”. Reauthorization runs on documented response, not the calendar: BCBS Michigan requires “clinical documentation ... that the medication is providing clinical benefit,” and Centene renews when the “[m]ember is responding positively to therapy.”

Site of care

Fifteen rules turn the self-administration question into a claim requirement, since the subcutaneous syringe and ClickJect autoinjector exist as an alternative to the IV infusion. BCBS Kansas requires the physician to attest that “the patient or caregiver is not competent or is physically unable to administer the Orencia product FDA labeled for self-administration,” and Blue Shield of California lists a “preferred site of service, including the home, a physician's office, or an independent infusion center not associated with a hospital.”

CareFirst allows “the first two infusions may be permitted in the hospital outpatient setting” before steering to a lower-cost site; Horizon, Premera, Regence, BCBS Arkansas and BCBS South Carolina each point to a separate site-of-care policy rather than writing the rule directly into the abatacept policy.

ICD-10-CM by indication

Four indications, four codes, each with its own share of the Clearance corpus.

Quantity limits and the J0129 MUE

CMS sets the J0129 Medically Unlikely Edit at 100 units a day, 1,000 mg, the labeled maximum for any single adult band or the GvHD ceiling. Fifteen payer policies write their own quantity limit alongside it: BCBS HCSC caps the fill at “Orencia Abatacept For IV Soln 250 MG 250 MG 4 Vials 28 Days,” and Wellmark writes “4 vials or syringes/auto-injectors per 28 days,” both matching the 1,000 mg adult ceiling.

BCBS Minnesota and Capital Blue cap GvHD prophylaxis at “400 billable units per 29 days,” the four 100-unit doses across the transplant course, and UnitedHealthcare and Centene both authorize exactly four doses.

Check the patient’s actual policy: See Orencia coverage by payer →

Orencia cost & financial access

Medicare ASP+6%: $45.937 / 10 mg · $3,445.27 / 750 mg. Administration (96365) allows $67.14 more, so the 750 mg claim allows $3,512.41 total; at 20% coinsurance with the Part B deductible met, the patient owes $702.48.

13 doses a year (750 mg IV every 4 weeks for a 60 to 100 kg adult after the week 0, 2 and 4 induction infusions (a maintenance year is 13 infusions; the first year is 14)) at $3,512.41 per infusion — drug plus 96365 administration — total $45,661.40 before the sequester. That is the full annual drug-plus-administration cost for a patient staying on schedule, before benefits or assistance.

The other two weight bands price the same way: 500 mg (50 units) allows $2,296.85 for the drug alone, and 1,000 mg (100 units) allows $4,593.70, both at the $45.937/10 mg ASP rate before the 96365 administration fee.

At 20% coinsurance with the $283 Part B deductible already met, the patient owes $702.48 of the 750 mg claim ($689.05 drug plus $13.43 infusion). Commercial plans pay a contracted rate that varies by payer and state; 37 of 37 payer price files in this site's data carry a J0129 rate.

Aetna's all-states commercial median is $46.42 per unit (10 mg), close to the $45.937 ASP Medicare rate. At 75 units, that prices the 750 mg dose at $3,481.50, about $36 more than Medicare allows for the drug alone ($3,445.27).

Patient cost

Patient responsibility = payer allowed rate − benefits adjustment − assistance. Confirm which weight band the encounter reflects before estimating: the drug portion alone ranges from $2,296.85 at 500 mg to $4,593.70 at 1,000 mg.

Calculate a Orencia patient estimate →

Copay & financial assistance

ORENCIA On Call caps a commercially insured patient's drug cost at $5 a month, up to $15,000 a year, but it pays only the drug, never the infusion or the office visit, and it excludes Medicare, Medicaid, TRICARE, VA and any other government plan.

The BMS Patient Assistance Foundation ships Orencia free to an uninsured patient facing financial hardship, drug cost only; the administration is billed separately. The RA and PsA foundation funds that once listed abatacept are TotalAssist Rheumatoid Arthritis and TotalAssist Psoriatic Arthritis; the one other fund that still matches Orencia's J-code, HealthWell's ANCA-associated vasculitis grant, does not apply to RA, PsA, pJIA or GvHD prophylaxis (check each fund's current status on the funds list).

See current Orencia assistance programs →

Common Orencia errors & fixes